Literature DB >> 2702984

Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer.

O Stål1, S Wingren, J Carstensen, L E Rutqvist, L Skoog, C Klintenberg, B Nordenskjöld.   

Abstract

Tumors from 472 women with primary breast cancer were analyzed by flow cytometry. Divided into four categories, DNA ploidy showed significant association with disease recurrence and mortality. When allowance was made for its correlation with nodal status and estrogen receptor (ER) content, DNA ploidy did not add prognostic information. S-phase fraction was estimated in 290 DNA histograms. In contrast, it was significantly related to recurrence and mortality when controlling for nodal status, tumor size and ER content. When the follow-up was divided into two periods DNA ploidy and S-phase fraction showed association with disease recurrence in the first period only (less than 2.5 years), while the association with mortality was valid for both periods. Light scatter was measured in 234 samples. A low light scatter variability for the stemline nuclei was related to a high recurrence rate during the early follow-up period. In conclusion, DNA flow cytometry adds prognostic information concerning breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702984     DOI: 10.1016/0277-5379(89)90023-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  11 in total

1.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

2.  Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas.

Authors:  S B Ewers; R Attewell; B Baldetorp; A Borg; E Långström; D Killander
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

3.  The relationship between lymph node metastases and DNA-ploidy status as prognostic factors in invasive breast cancer.

Authors:  M Noguchi; N Ohta; N Koyasaki; T Taniya; I Miyazaki; Y Mizukami
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

4.  S-phase determination of immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence.

Authors:  S Wingren; O Stål; J Carstensen; X F Sun; B Nordenskjöld
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872

5.  Genetic evolution of breast cancers. III: Age-dependent variations in the correlations between biological indicators of prognosis.

Authors:  Y Remvikos; H Magdelenat; B Dutrillaux
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

6.  The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up.

Authors:  S Toikkanen; H Joensuu; P Klemi
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

7.  Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.

Authors:  S Wingren; O Stål; B Nordenskjöld
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

8.  DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.

Authors:  M Karlsson; B Boeryd; J Carstensen; B Kågedal; A T Bratel; S Wingren
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

9.  Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer.

Authors:  P D Stanton; T G Cooke; S J Oakes; J Winstanley; S Holt; W D George; G D Murray
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

10.  Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

Authors:  O Stål; J Carstensen; T Hatschek; B Nordenskjöld
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.